Searchable abstracts of presentations at key conferences in endocrinology

ea0090ep786 | Pituitary and Neuroendocrinology | ECE2023

De-escalation treatment with pasireotide for aggressive acromegaly: A long-term experience

Menotti Sara , Giampietro Antonella , Chiloiro Sabrina , Pontecorvi Alfredo , De Marinis Laura , Bianchi Antonio

Introduction: Pasireotide long acting release (LAR) is approved for second line treatment of acromegaly. We present 3 patients with aggressive acromegaly treated with a personalized de-escalation approach.Case 1: A 61-year-old female affected by acromegaly reisistant on first-line SSAs. In 2015 therapy was switched to pasireotide LAR 60 mg every 28 days. After two years, the IGF-I level touched the lower age range and therapy was downscaled to pasireotid...

ea0090ep1140 | Late Breaking | ECE2023

Cushing’s disease: a rare case of long-term pasireotide therapy

Veleno Miriam , Chiloiro Sabrina , Giampietro Antonella , Bianchi Antonio , De Marinis Laura

Background: Cushing’s disease, the most common cause of endogenous Cushing’s syndrome, is caused by a pituitary tumor secreting adrenocorticotropic hormone (ACTH). Careful selection of treatment and management of the disease and associated comorbidities are necessary to improve prognosis.Case Presentation: A 32-year-old patient came to our observation for appearance of weight gain with abdominal obesity, hirsutism and amenorrhea. On suspicion o...

ea0090ep1145 | Late Breaking | ECE2023

Pasireotide LAR Treatment for Non-functioning Pituitary Adenoma: A Case Report

Menotti Sara , Giampietro Antonella , Giorgio D'Alessandris Quintino , Chiloiro Sabrina , De Marinis Laura , Bianchi Antonio

Introduction: Non functioning pituitary adenomas (NFPAs) are the most common type of pituitary tumors and are often invasive, resulting in high relapse rates. The post-surgical treatment for NFPAs remains a debated issue and include radiation therapy and additional surgery. Several clinical studies have demonstrated that dopaminergic and somatostatin receptors (SSTRs) are widely expressed in NFPAs. Furthermore, recent studies have shown the potential effectiveness of somatosta...

ea0041ep929 | Pituitary - Clinical | ECE2016

Clinical management of pituitary teratomas and safety of rhgh replacement therapy: a case report

Chiloiro Sabrina , Giampietro Antonella , Bima Chiara , Bracaccia Maria Elena , De Marinis Laura

Teratomas comprise 0.5% of all intracranial tumors. 15 cases of sellar teratoma have been described in the last 24 years (yrs). A 29-yrs female pan-hypopituitaric patient (pt) was admitted to our Pituitary Unit. At 6-yrs age, for polyuria and growth delay, an endocrine evaluation revealed diabetes insipidus and hypopituitarism. Cranial contrasted-MRI (cc-MRI) showed pituitary stalk thickening and a low intensity suprasellar lesion. Histological examination (HE) was suggestive ...

ea0049oc12.5 | Pituitary Clinical | ECE2017

Effects of pegvisomant and somatostatin receptor ligands on risk of vertebral fractures in patients with Acromegaly

Chiloiro Sabrina , Mazziotti Gherardo , Giampietro Antonella , Formenti Anna Maria , Bianchi Antonio , Mormando Marilda , Pontecorvi Alfredo , Giustina Andrea , De Marinis Laura

Acromegalic osteopathy is an emerging complication of chronic GH excess characterized by increase in bone turnover, deterioration in bone microarchitecture and high risk of vertebral fractures (VFs). Medical therapies may exert direct effects on peripheral targets leading to improvement of clinical outcomes regardless of biochemical control of acromegaly. In this longitudinal study, we compared the effects pegvisomant (PegV) and somatostatin receptor ligands (SRLs) on VF risk ...

ea0049ep991 | Pituitary - Clinical | ECE2017

Biochemical normalization in acromegaly after 79 months’ treatment with Pasireotide: case report

Bima Chiara , Chiloiro Sabrina , Iacovazzo Donato , Tartaglione Tommaso , Bracaccia Maria Elena , Giampietro Antonella , Bianchi Antonio , De Marinis Laura

Pasireotide, a multireceptor-targeted somatostatin analogue, was approved for the treatment of acromegaly, after being studied in two large, randomised, multi-center clinical trials. We reported the history of a 76 years old man affected by acromegaly, treated with Pasireotide long acting release (LAR) as first line therapy. Acromegaly was diagnosed in 2009, as the result of endocrinological investigation suggested by altered facial appearance and macroglossia. Hormonal assays...

ea0035p576 | Endocrine tumours and neoplasia | ECE2014

Correlation between atypical pituitary adenomas and Ki-67 Li: clinical and prognostic aspects

Chiloiro Sabrina , Bianchi Antonio , Giampietro Antonella , Iacovazzo Donato , Trapasso Barbara , Piacentini Serena , Tartaglione Linda , Lugli Francesca , De Marinis Laura

Introduction: In 2004, the WHO defined atypical pituitary adenomas (APAs) those with Ki-67 >3%, excessive p53 expression and increased mitotic activity. The usefulness of this classification is still controversial.Aim: To compare the clinical and prognostic features in a series of typical and atypical pituitary adenomas.Materials and methods: We retrospectively reviewed 343 consecutive PAs. APAs represented 18.7% of the cases. ...

ea0070aep608 | Pituitary and Neuroendocrinology | ECE2020

Metabolism of glucose in patients with acromegaly treated with Pegvisomant and/or Pasireotide LAR after resistance to first generation somatostatin receptor ligands

Chiloiro Sabrina , Giampietro Antonella , Bianchi Antonio , Maria Formenti Anna , Maya Fleseriu Cara , Pontecorvi Alfredo , Giustina Andrea , De Marinis Laura

Introduction: Acromegaly (Acro) is characterized by insulin sensitivityreduction, glucose intolerance (IGT) and diabetes mellitus (DM2 in 15%–38% of patients). Studies that investigated action of medical therapies for acro on glucose metabolism, didn’t provide conclusive data. Association between blood glucose (BG) levels and serum IGF-I levels in patients with DM2 and acro has been suggested, however,IGF-I levels and hemoglobin A1c (HbA1c) correlation is still con...

ea0022p112 | Bone/Calcium | ECE2010

Risk of vertebral fractures in osteoporotic women: definition of a clinically relevant scale of risk

Fusco Alessandra , Pola Enrico , Mormando Marilda , Colangelo Debora , Aurelio Nasto Luigi , Bianchi Antonio , Ambrogio Logroscino Carlo , De Marinis Laura

Introduction: Osteoporosis is a disease characterized by a low bone mass and the development of nontraumatic fractures, most commonly in the spine. However, bone mineral density (BMD) alone is not completely satisfactory in vertebral fracture risk assessment.Aim of the study: To identify clinical and laboratoristic factors associated with an increased risk of vertebral fractures in osteoporotic Caucasian women and to define a new clinically relevant scal...

ea0022p542 | Male reproduction | ECE2010

Initial characterization of the human seminal plasma proteome in a fertile normogonadic man by top-down strategy

Milardi Domenico , Vincenzoni Federica , Grande Giuseppe , Antonella Giampietro , Pontecorvi Alfredo , Castagnola Massimo , De Marinis Laura , Marana Riccardo

Human seminal plasma contains a large array of proteins required for the normal physiology of spermatozoa and fertilization. To provide informations about the physiological mechanisms of male fertility we performed proteomic studies on human seminal plasma by a top-down approach. A semen sample was collected in a fertile normospermic man (sperm concentration 60×106 per ml; progressive motility 58%; normal morphology 45%). Hormonal blood assay was performed: tes...